
    
      This is a prospective study that has two groups of patients as determined by their prescribed
      treatment plan. Group A (control group) are patients with metastatic triple-negative breast
      cancer (TNBC) who receive chemotherapy only (current standard of care). Group B (experimental
      group) are patients with mTNBC who receive a combination of chemotherapy and IT immunotherapy
      (Atezolizumab) which is a standard of care for patients whose tumor express >1% of PD-L1
      molecules. T-cell cytokines will be measures prior to treatment and at multiple time points
      during the treatment.
    
  